Farnesyltransferase inhibitors and human malignant pleural mesothelioma: A first-step comparative translational study

Clinical Cancer Research

Volumn 11, Issue 5, 2005, Pages 2026-2037

  Cesario, Alfredo ^a,e   Catassi, Alessia ^b   Festi, Luigi ^d   Imperatori, Andrea ^d   Pericelli, Andrea ^d   Galetta, Domenico ^a   Margaritora, Stefano ^a   Porziella, Venanzio ^a   Cardaci, Vittorio ^e   Granone, Pierluigi ^a   Dominioni, Lorenzo ^d   Russo, Patrizia ^c  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF INSUBRIA   (Italy)

^e IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; AMPHIREGULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GUANOSINE TRIPHOSPHATE; LONAFARNIB; MANUMYCIN; METHOTREXATE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; RPR 115135; TIPIFARNIB; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MESOTHELIUM CELL; PLEURA MESOTHELIOMA; PRENYLATION; PRIORITY JOURNAL; TUMOR BIOPSY; WESTERN BLOTTING;

ALKYL AND ARYL TRANSFERASES; BLOTTING, WESTERN; CELL PROLIFERATION; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; LIGANDS; MESOTHELIOMA; PLEURAL NEOPLASMS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 20144388693     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1450     Document Type: Article

References (53)

1. Pelucchi C, Malvezzi M, La Vecchia C, Levi F, Decarli A, Negri E. The mesothelioma epidemic in Western Europe: an update. Br J Cancer 2004;90:1022-4.
2. Hemminki K, Li X. Mesothelioma incidence seems to have leveled off in Sweden. Int J Cancer 2003;103:145-6.
3. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999;79:666-72.
4. Cugell DW, Kamp DW. Asbestos and the pleura: a review. Chest 2004;125:1103-17.
5. van Ruth S, Baas P, Zoetmulder FA. Surgical treatment of malignant pleural mesothelioma: a review. Chest 2003;123:551-61.
6. Treasure T, Waller D, Swift S, Peto J. Radical surgery for mesothelioma. Br Med J 2004;328:237-8.
7. Sugarbaker DJ, Heher EC, Lee TH, et al. Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1991; 102:10-4; discussion 14-5.
8. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44.
9. Trupiano JK, Geisinger KR, Willingham MC, et al. Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol 2004;17:476-81.
10. Cai YC, Roggli V, Mark E, Cagle PT, Fraire AE. Transforming growth factor α and epidermal growth factor receptor in reactive and malignant mesothelial proliferations. Arch Pathol Lab Med 2004; 128:68-70.
11. Janne PA, Taffaro ML, Salgia R, Johnson BE. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 2002;62:5242-7.
12. Yamada S, Taketomi T, Yoshimura A. Model analysis of difference between EGF pathway and FGF pathway. Biochem Biophys Res Commun 2004;314:1113-20.
13. Zhang T, Ma J, Cao X. Grb2 regulates Stat3 activation negatively in epidermal growth factor signalling. Biochem J 2003;376:457-64.
14. Cai T, Nishida K, Hirano T, Khavari PA. Gab1 and SHP-2 promote Ras/MAPK regulation of epidermal growth and differentiation. J Cell Biol 2002;159:103-12.
15. Saito T, Okada S, Ohshima K, et al. Differential activation of epidermal growth factor receptor (ErbB1/EGFR) downstream signaling pathways by betacellulin and EGF. Endocrinology 2004;149:4232-43.
16. Holgado-Madruga M, Wong AJ. Role of the Grb2-associated binder 1/SHP-2 interaction in cell growth and transformation. Cancer Res 2004;64:2007-15.
17. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-2.
18. Cox AD, Der CJ. The dark side of Ras: regulation of apoptosis. Oncogene 2003;22:8999-9006.
19. Kinbara K, Goldfinger LE, Hansen M, Chou FL, Ginsberg MH. Ras GTPases: integrals' friends or foes? Nat Rev Mol Cell Biol 2003;4:767-76.
20. Herrmann C. Ras-effector interactions: after one decade. Curr Opin Struct Biol 2003;13:122-9.
21. Sebti SM, Adjei AA. Farnesyltransferase inhibitors. Semin Oncol 2004;31:28-39.
22. Russo P, Loprevite M, Cesario A, Ardizzoni A. Farnesylated proteins as anticancer drug targets: from laboratory to the clinic. Curr Med Chem Anti-Cane Agents 2004;4:123-38.
23. Sizemore N, Cox AD, Bamard JA, et al. Pharmacological inhibition of Ras-transformed epithelial cell growth is linked to down-regulation of epidermal growth factor-related peptides. Gastroenterology 1999;117:567-76.
24. Norgaard P, Law BK, Plovisson HS, Moses HL. Farnesyltransferase inhibitor-induced regression of mammary tumors in TGF α and TGF α/neu transgenic mice correlates with inhibition of map kinase and p70s6 kinase phosphorylation. Ann N Y Acad Sci 1999;886:265-8.
25. Norgaard P, Law B, Joseph H, et al. Treatment with famesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) α and TGF α/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin Cancer Res 1999;5:35-42.
26. Ottoboni C, Crippa A, Falugi C, Russo P. Induction of micronuclei by a new non-peptidic mimetic farnesyltransferase inhibitor RPR-115135: role of gene mutations. Mutagenesis 2001;16:423-30.
27. Trombino S, Cesario A, Margaritora S, et al. α7-Nicotinic acetylcholine receptors affect growth regulation of human mesothelioma cells: role of mitogen-activated protein kinase pathway. Cancer Res 2004;64:135-45. Erratum in Cancer Res 2004;64:1559.
28. Pass HI, Liu Z, Wali A, et al. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res 2004;10:849-59.
29. Gordon GJ, Jensen RV, Hsiao LL, et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 2003;95:598-605.
30. Gordon GJ, Jensen RV, Hsiao LL, et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 2002;62:4963-7.
31. Valente P, Arzani D, Cesario A, Margaritora S, Carbone E, Russo P. TNF increases camptothecin-induced apoptosis by inhibition of NF-κB. Eur J Cancer 2003;39:1468-77.
32. Russo P, Arzani D, Trombino S, Falugi C. c-myc down-regulation induces apoptosis in human cancer cell lines exposed to RPR-115135 (C31H29NO4), a non-peptidomimetic farnesyltransferase inhibitor. J Pharmacol Exp Ther 2003;304:37-47.
33. Russo P, Malacarne D, Falugi C, Trombino S, O'Connor PM. RPR-115135, a farnesyltransferase inhibitor, increases 5-FU-cytotoxicity in ten human colon cancer cell lines: role of p53. Int J Cancer 2002;100:266-75.
34. Winter-Vann AM, Kamen BA, Bergo MO, et al. Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate. Proc Natl Acad Sci U S A 2003;100:6529-34.
35. Philips MR. Methotrexate and Ras methylation: a new trick for an old drug? Sci STKE 2004:225:pe13.
36. Kurzrock R, Kantarjian HM, Cortes JE, et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood 2003;102:4527-34.
37. Ono M, Hirata A, Kometani T, et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 2004;3:465-72.
38. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003;9:2316-26.
39. Burke P, Schooler K, Wiley HS. Regulation of EGF receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell 2001;12:1897-910.
40. Habib AA, Chun SJ, Neel BG, Vartanian T. Increased expression of epidermal growth factor receptor induces sequestration of extracellular signal-related kinases and selective attenuation of specific epidermal growth factor-mediated signal transduction pathways. Mol Cancer Res 2003;1:219-33.
41. Zhao R, Goldman ID. Resistance to antifolates. Oncogene 2003;22:7431-57.
42. Young SG, Ambroziak P, Kim E, Clarke S. Postisoprenylation protein processing: C′ (CaaX) endoproteases and isoprenylcysteine carboxyl methyltransferase. In: Tamanoi F, Sigman DS, editors. The enzymes. Vol. 21. San Diego (CA): Academic Press; 2000. p. 155-213.
43. Chen Z, Otto JC, Bergo MO, Young SG, Casey PJ. The C-terminal polylysine region and methylation of K-Ras are critical for the interaction between K-Ras and microtubules. J Biol Chem 2000;275:41251-7.
44. Lobell RB, Liu D, Buser CA, et al. Preclinical and clinical pharmacodynamic assessment of L-778, 123, a dual inhibitor of farnesyl: protein transferase and geranylgeranyl:protein transferase type-1. Mol Cancer Ther 2002;1:747-58.
45. Sepp-Lorenzino L, Ma Z, Rands E, et al. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 1995;55:5302-9.
46. Falugi C, Trombino S, Granone P, Margaritora S, Russo P. Increasing complexity of farnesyltransferase inhibitors activity: role in chromosome instability. Curr Cancer Drug Targets 2003;3:109-18.
47. Rose WC, Lee FY, Fairchild CR, et al. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res 2001;61:7507-17.
48. Manne V, Lee FY, Bol DK, et al. Apoptotic and cytostatic farnesyltransferase inhibitors have distinct pharmacology and efficacy profiles in tumor models. Cancer Res 2004;64:3974-80.
49. Cesario A, Galetta D, Russo P, Margaritora S, Granone P. The role of the surgeon in translational research. Lancet 2003;362:1082.
50. Yeatman TJ. The future of cancer management: translating the genome, transcriptome, and proteome. Ann Surg Oncol 2003;10:7-14.
51. Kreeger K. From bench to bedside. Nature 2003;424:1090-1.
52. Apolone G. Clinical and outcome research in oncology. The need for integration. Health Qual Life Outcomes 2003;1:3.
53. Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 2004;22:247-306.